HK Stock Market Move | Pharmaceutical company AJA Health (02617) plunged 18% in early trading with a total market value of less than HKD 70 billion. The group did not achieve any revenue from its main business in the first half of the year.

Yaoje Ankang (02617) was heavily speculated on by funds last week, with a cumulative increase of over 200% during the period. The stock plummeted 18% in early trading today, falling 12.99% to HK$167.5 as of the time of publication, with a turnover of HK$3.33 billion and a total market value falling below HK$70 billion. In terms of news, the Shanghai Stock Exchange and the Shenzhen Stock Exchange recently announced that Yaoje Ankang has been included in the list of Hong Kong Stock Connect targets, effective from September 8. Public information shows that Yaoje Ankang focuses on discovering and developing small molecule innovative therapies for tumors, inflammation, and cardiovascular metabolic diseases. As of June 30, 2025, the company's main pipeline includes six clinical stage candidate products and multiple preclinical candidate products. It is worth noting that the company's core product, Tianengotinin (TT-00420), has recently received multiple favorable news. It is worth noting that Yaoje Ankang previously announced its interim performance, with the Group not generating main business income in the first half of the year. Other income and gains decreased from HK$10.4 million in the first half of 2024 to HK$3.6 million, a decrease of 65.1%. The company stated that this decrease was mainly due to a reduction of HK$4.1 million in bank deposit interest and financial income, and a reduction of HK$2.7 million in government grants. R&D costs decreased by 30.9% to HK$98.4 million. In addition, Yaoje Ankang recorded a pre-tax loss of HK$123 million in the first half of the year, an improvement compared to the loss of HK$160 million in the same period of 2024.